Table 2.
Effect of on-site PrEP access on HIV incidence
| Number of infections/person-years | Incidence | Adjusted incidence rate ratio*(95% CI) | p value | Adjusted incidence rate ratio†(95% CI) | p value | |
|---|---|---|---|---|---|---|
| Including study visits with on-site PrEP access | ||||||
| Before access | 133/2860 | 4·65% | .. | .. | .. | .. |
| After access | 12/556 | 2·16% | 0·45 (0·25–0·81) | 0·0076 | 0·45 (0·25–0·82) | 0·0085 |
| 180 days before versus 180 days after on-site PrEP access | ||||||
| Before access | 46/919 | 5·00% | .. | .. | .. | .. |
| After access | 11/481 | 2·29% | 0·44 (0·23–0·85) | 0·015 | 0·43 (0·22–0·83) | 0·012 |
Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis.
*
Adjusted for study site and randomisation group.
†
Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only).